Furthermore, the results of a clinical trial on melanoma demonstrated higher frequencies of VISTA+ and Treg cells in patients after anti-PD-1 treatment in comparison with untreated patients, indicating that negative IC regulation by VISTA may be an important potential mechanism of acquired resistance in melanoma patients treated with anti-PD-1 (33). The gene discussed is VSIR; the disease is melanoma.